Heron Therapeutics Management
Management criteria checks 2/4
Heron Therapeutics' CEO is Craig Collard, appointed in Apr 2023, has a tenure of 1.67 years. directly owns 0.18% of the company’s shares, worth $421.41K. The average tenure of the management team and the board of directors is 1.5 years and 3.3 years respectively.
Key information
Craig Collard
Chief executive officer
US$5.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03CEO
Craig Collard (58 yo)
1.7yrs
Tenure
US$5,486
Compensation
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$5.49k | 0.18% $ 421.4k | |
| Executive VP & CFO | 1.5yrs | US$1.76m | 0.071% $ 170.6k | |
| Executive VP & Chief Development Officer | 1.5yrs | US$1.71m | 0.068% $ 162.9k | |
| Vice President of Marketing | 1.3yrs | no data | no data | |
| Senior Vice President of Human Resources | 9.3yrs | no data | no data | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 1.9yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Executive Director | no data | no data | no data |
1.5yrs
Average Tenure
55yo
Average Age
Experienced Management: HRTX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$5.49k | 0.18% $ 421.4k | |
| Independent Director | 10.9yrs | US$11.02m | 0.034% $ 82.0k | |
| Independent Director | 8.5yrs | US$70.51k | 0.034% $ 82.5k | |
| Director | less than a year | no data | no data | |
| Independent Director | 3.3yrs | US$65.63k | 0.035% $ 83.7k | |
| Independent Chairman | 1.8yrs | US$545.53k | 0.0062% $ 15.0k | |
| Independent Director | 3.3yrs | US$55.00k | 0.035% $ 83.7k |
3.3yrs
Average Tenure
57yo
Average Age
Experienced Board: HRTX's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Heron Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Boran Wang | Aegis Capital Corporation |
| Tazeen Ahmad | BofA Global Research |
| Jonathan Aschoff | Brean Capital |